Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Large Growth in Short Interest

Posted by George Bondi on Jun 11th, 2026

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 50,407 shares, an increase of 327.4% from the May 14th total of 11,793 shares. Based on an average trading volume of 359,949 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

CHGCY has been the topic of a number of recent research reports. Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

Check Out Our Latest Stock Analysis on Chugai Pharmaceutical

Chugai Pharmaceutical Trading Down 0.4%

CHGCY stock traded down $0.09 during mid-day trading on Thursday, hitting $23.19. The stock had a trading volume of 420,444 shares, compared to its average volume of 235,537. The firm has a fifty day simple moving average of $25.81 and a 200 day simple moving average of $27.23. The firm has a market capitalization of $76.32 billion, a P/E ratio of 25.76 and a beta of 0.58. Chugai Pharmaceutical has a 52 week low of $19.50 and a 52 week high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its quarterly earnings results on Friday, April 24th. The company reported $0.22 earnings per share for the quarter. The company had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. As a group, equities analysts expect that Chugai Pharmaceutical will post 0.98 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.